Pim van der Harst

Prof. Pim van der Harst

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TPThe Million Veteran Program
The Million Veteran Program
EEEvangelos Evangelou
Evangelos Evangelou
HWHelen R. Warren
Helen R. Warren
DMDavid Mosen-Ansorena
David Mosen-Ansorena
BMBorbala Mifsud
Borbala Mifsud
MCMark Caulfield
Mark Caulfield
High blood pressure is a highly heritable and modifiable risk factor for cardiovascular disease. We report the largest genetic association study of blood pressure traits (systolic, diastolic and pulse pressure) to date in over 1 million people of European ancestry. We identify 535 novel blood pressure loci that not only offer new biological insights into blood pressure regulation but also highlight shared genetic architecture between blood pressure and lifestyle exposures. Our findings identify new biological pathways for blood pressure regulation with potential for improved cardiovascular disease prevention in the future.

2 February 2018 in Circulation Research
Verified
Journal Article
Open access
PDF file
PHPim van der Harst
Pim van der Harst
NVNiek Verweij
Niek Verweij
Rationale:: Coronary artery disease (CAD) is a complex phenotype driven by genetic and environmental factors. Ninety-seven genetic risk loci have been identified to date, but the identification of additional susceptibility loci might be important to enhance our understanding of the genetic architecture of CAD. Objective:: To expand the number of genome-wide significant loci, catalog functional insights, and enhance our understanding of the genetic architecture of CAD. Methods and Results:: We performed a genome-wide association study in 34 541 CAD cases and 261 984 controls of UK Biobank resource followed by replication in 88 192 cases and 162 544 controls from CARDIoGRAMplusC4D. We identified 75 loci that replicated and were genome-wide significant ( P <5×10 −8 ) in meta-analysis, 13 of which had not been reported previously. Next, to further identify novel loci, we identified all promising ( P <0.0001) loci in the CARDIoGRAMplusC4D data and performed reciprocal replication and meta-analyses with UK Biobank. This led to the identification of 21 additional novel loci reaching genome-wide significance ( P <5×10 −8 ) in meta-analysis. Finally, we performed a genome-wide meta-analysis of all available data revealing 30 additional novel loci ( P <5×10 −8 ) without further replication. The increase in sample size by UK Biobank raised the number of reconstituted gene sets from 4.2% to 13.9% of all gene sets to be involved in CAD. For the 64 novel loci, 155 candidate causal genes were prioritized, many without an obvious connection to CAD. Fine mapping of the 161 CAD loci generated lists of credible sets of single causal variants and genes for functional follow-up. Genetic risk variants of CAD were linked to development of atrial fibrillation, heart failure, and death. Conclusions:: We identified 64 novel genetic risk loci for CAD and performed fine mapping of all 161 risk loci to obtain a credible set of causal variants. The large expansion of reconstituted gene sets argues in favor of an expanded omnigenic model view on the genetic architecture of CAD.

9 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
SGSarah E. Graham
Sarah E. Graham
SCShoa L. Clarke
Shoa L. Clarke
KWKuan-Han H. Wu
Kuan-Han H. Wu
Stavroula KanoniStavroula Kanoni
Stavroula Kanoni
GZGreg J. M. Zajac
Greg J. M. Zajac
CWCristen J. Willer
Cristen J. Willer

31 May 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LSLifelines Cohort Study
Lifelines Cohort Study
MWMatthias Wuttke
Matthias Wuttke
VPV. A. Million Veteran Program
V. A. Million Veteran Program
YLYong Li
Yong Li
MLMan Li
Man Li
CPCristian Pattaro
Cristian Pattaro
Chronic kidney disease (CKD) is responsible for a public health burden with multi-systemic complications. Through trans-ancestry meta-analysis of genome-wide association studies of estimated glomerular filtration rate (eGFR) and independent replication (n = 1,046,070), we identified 264 associated loci (166 new). Of these, 147 were likely to be relevant for kidney function on the basis of associations with the alternative kidney function marker blood urea nitrogen (n = 416,178). Pathway and enrichment analyses, including mouse models with renal phenotypes, support the kidney as the main target organ. A genetic risk score for lower eGFR was associated with clinically diagnosed CKD in 452,264 independent individuals. Colocalization analyses of associations with eGFR among 783,978 European-ancestry individuals and gene expression across 46 human tissues, including tubulo-interstitial and glomerular kidney compartments, identified 17 genes differentially expressed in kidney. Fine-mapping highlighted missense driver variants in 11 genes and kidney-specific regulatory variants. These results provide a comprehensive priority list of molecular targets for translational research.

11 June 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CRCarolina Roselli
Carolina Roselli
MCMark D. Chaffin
Mark D. Chaffin
LWLu-Chen Weng
Lu-Chen Weng
SAStefanie Aeschbacher
Stefanie Aeschbacher
GAGustav Ahlberg
Gustav Ahlberg
PEPatrick T. Ellinor
Patrick T. Ellinor

1 February 2014 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
JVJana V van Vliet-Ostaptchouk
Jana V van Vliet-Ostaptchouk
MNMarja-Liisa Nuotio
Marja-Liisa Nuotio
SSSandra N Slagter
Sandra N Slagter
DDDany Doiron
Dany Doiron
KFKrista Fischer
Krista Fischer
BWBruce H.R. Wolffenbuttel
Bruce H.R. Wolffenbuttel
Not all obese subjects have an adverse metabolic profile predisposing them to developing type 2 diabetes or cardiovascular disease. The BioSHaRE-EU Healthy Obese Project aims to gain insights into the consequences of (healthy) obesity using data on risk factors and phenotypes across several large-scale cohort studies. Aim of this study was to describe the prevalence of obesity, metabolic syndrome (MetS) and metabolically healthy obesity (MHO) in ten participating studies. Ten different cohorts in seven countries were combined, using data transformed into a harmonized format. All participants were of European origin, with age 18–80 years. They had participated in a clinical examination for anthropometric and blood pressure measurements. Blood samples had been drawn for analysis of lipids and glucose. Presence of MetS was assessed in those with obesity (BMI ≥ 30 kg/m2) based on the 2001 NCEP ATP III criteria, as well as an adapted set of less strict criteria. MHO was defined as obesity, having none of the MetS components, and no previous diagnosis of cardiovascular disease. Data for 163,517 individuals were available; 17% were obese (11,465 men and 16,612 women). The prevalence of obesity varied from 11.6% in the Italian CHRIS cohort to 26.3% in the German KORA cohort. The age-standardized percentage of obese subjects with MetS ranged in women from 24% in CHRIS to 65% in the Finnish Health2000 cohort, and in men from 43% in CHRIS to 78% in the Finnish DILGOM cohort, with elevated blood pressure the most frequently occurring factor contributing to the prevalence of the metabolic syndrome. The age-standardized prevalence of MHO varied in women from 7% in Health2000 to 28% in NCDS, and in men from 2% in DILGOM to 19% in CHRIS. MHO was more prevalent in women than in men, and decreased with age in both sexes. Through a rigorous harmonization process, the BioSHaRE-EU consortium was able to compare key characteristics defining the metabolically healthy obese phenotype across ten cohort studies. There is considerable variability in the prevalence of healthy obesity across the different European populations studied, even when unified criteria were used to classify this phenotype.